$18.32−0.35 (−1.87%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Acadia Pharmaceuticals (ACAD) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Sep 30, 2026*: more funds added or entered than trimmed or exited, mild accumulation (65 new · 148 increased · 89 reduced · 59 closed). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 352 filers, Sep 30, 2026
# 13F FUNDS
352
13F VALUE
$3.5B
172.7M shares
Not reported in the company's filings for this period.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 3,321 | $20.88 | ↗ |
| Oct 15, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Acquired · Grant / award | 6,815 | — | ↗ |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Acquired · Option exercise | 14,292 | $17.84 | ↗ |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 5,000 | $29.00 | ↗ |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 9,292 | $29.34 | ↗ |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Disposed · Option exercise | 14,292Stock Option (Right to Buy) | — | ↗ |
| Aug 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Acquired · Option exercise | 5,849 | $17.84 | ↗ |
| Aug 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 5,849 | $29.00 | ↗ |
| Aug 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Disposed · Option exercise | 5,849Stock Option (Right to Buy) | — | ↗ |
| Jul 30, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Disposed · Open-market sale | 16,508 | $26.13 | ↗ |
| Jul 30, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Disposed · Open-market sale | 50 | $26.17 | ↗ |
| Jul 29, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Acquired · Option exercise | 32,272 | — | ↗ |
| Jul 29, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Disposed · Option exercise | 32,272Restricted Stock Units | — | ↗ |
| Jun 26, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Disposed · Open-market sale | 11,421 | $26.08 | ↗ |
| May 29, 2026 | BAKER BROS. ADVISORS LP | director | Acquired · Grant / award | 18,622 | — | ↗ |
| May 29, 2026 | BAKER BROS. ADVISORS LP | director | Acquired · Grant / award | 18,622 | — | ↗ |
| May 29, 2026 | BAKER BROS. ADVISORS LP | director | Acquired · Grant / award | 32,008Non- Qualified Stock Option (right to buy) | — | ↗ |
| May 29, 2026 | BAKER BROS. ADVISORS LP | director | Acquired · Grant / award | 32,008Non- Qualified Stock Option (right to buy) | — | ↗ |
| May 29, 2026 | Ndu Adora | director | Acquired · Option exercise | 8,107 | — | ↗ |
| May 29, 2026 | Ndu Adora | director | Disposed · Option exercise | 8,107Restricted Stock Units | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold Acadia Pharmaceuticals?
Acadia Pharmaceuticals was held by 352 13F filers as of Sep 30, 2026.
Not investment advice.

